



CZECH REPUBLIC

## **ISPOR Czech Republic Regional Chapter Annual Report 2009 Czech Pharmacoeconomic Society (ČFES)**

**Prepared by:** Prof. Jan Švihovec, MD, DrSc  
Head of Department of Pharmacology, 2<sup>nd</sup> Medical Faculty  
Charles University Prague  
jan.svihovec@lfmotol.cuni.cz

Czech Pharmacoeconomic Society was founded in June, 2005. Currently the chapter has 180 members from academia, pharmaceutical industry, contract-research organizations and health-insurance companies.

**The current Executive Board of the ISPOR Czech Regional Chapter is:**

**President: Jan Švihovec MD, PhD, MuDr**  
Professor, Department of Pharmacology, 2nd Medical Faculty  
Charles University, Prague, Czech Republic

**President-Elect: Tomáš Doležal MD, PhD, MuDr**  
Professor, Department of Pharmacology, 3rd Medical Faculty  
Charles University, Prague, Czech Republic

**Treasurer: Jana Skoupá MUDr**

The Executive Board was elected in 2009 for a period of 4 years.

For more information on ISPOR Czech Regional Chapter, please visit ISPOR website at [http://www.ispor.org/regional\\_chapters/Czech/index.asp](http://www.ispor.org/regional_chapters/Czech/index.asp) or please visit the Regional Chapter domestic website: [www.farmakoekonomika.cz](http://www.farmakoekonomika.cz) (please note this website is in Czech).

Enclosure: Czech Chapter Annual Report 2009

The society holds annual pharmacoeconomic conferences together with Slovak ISPOR chapter and also promotes educational activities. The members are also active in scientific research (poster presentations at international ISPOR congresses) and cooperate with health-insurance companies on pharmacoeconomic evaluation assessments.

There are also PhD programs in Prague (3<sup>rd</sup> Faculty of Medicine, Charles University), Hradec Králové (Pharmaceutical Faculty of Charles University) and Brno (Medical Faculty of Masaryk's University).

**Summary of 2009 activities:**

<b>Workshop on pricing and reimbursement system – March 2009</b>
<i>Target audience: Ministry of Health, State Institute for Drug Control, pharmaceutical industry, health insurance companies and Medical Societies.</i>
The workshop was to analyze the decision making process after more than 1 year since its introduction.
<b>Czech and Slovak Pharmaco-economy Conference – June 2009</b>
<i>Main topics: Cancer treatment, HTA, registries and outcomes research, cost-effectiveness analyses</i>
<b>Workshop – November 2009</b>
<i>Main topic: Learning from European HTA agencies</i>
Invited speakers Prof. Schlander (Germany); Prof. Paterson (Scotland)
<b>Cooperation on legislation changes – through 2009</b>
<i>Revision of cost-effectiveness definition.</i>
<i>Update of local Health-Economic Guidelines</i>
<b>Revision of submitted cost-effectiveness and budget impact analyses – through 2009</b>
<i>Cooperation with health insurance companies.</i>
<b>Participation at several national and international congresses and workshops with health-economy subjects</b>
<i>Czech and Slovak Conference of Revision Medicine – May 2009</i>
<i>Common symposium on Health Economy and HTA (joint Czech and Slovak activity) – October 2009</i>
<i>Presentation of HE topics and CEA during several medical conferences</i>
<b>Journal “Farmakoekonomika”</b>
<i>Presents local and international pharmaco-economic information and own pharmaco-economy and outcomes research studies.</i>

**Upcoming activities in 2010**

March 2010 – General assembly of the members of CFES
March 2010 – Workshop (reimbursement system)
June 2010 – Czech-Slovak Pharmacoeconomic Conference
November 2010 - Cooperation on presentations at ISPOR 13 <sup>th</sup> European Congress in Prague